Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-07, Vol.381 (4), p.338-348
Hauptverfasser:	Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene O
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antitumor activity Bladder cancer Cancer Chemotherapy Creatinine Drug dosages Editorials Enzyme inhibitors Fibroblast growth factor receptor 1 Fibroblast growth factor receptors Gene expression Humans Immune clearance Immunotherapy Kaplan-Meier Estimate Kinases Life Sciences Metastases Metastasis Middle Aged Mutation Neoplasm Metastasis - drug therapy Pharmaceutical sciences Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein-tyrosine kinase Protein-Tyrosine Kinases - antagonists & inhibitors Pyrazoles - administration & dosage Pyrazoles - adverse effects Quinoxalines - administration & dosage Quinoxalines - adverse effects R&D Receptors, Fibroblast Growth Factor - antagonists & inhibitors Receptors, Fibroblast Growth Factor - genetics Research & development Response rates Survival Treatment Outcome Urologic Neoplasms - drug therapy Urologic Neoplasms - genetics Urologic Neoplasms - pathology Urothelial carcinoma Urothelium
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1817323